Developer docs
API playgroundTry for free, no card

Search company profiles

Impulse Dynamics

Full company profile

uuid0000qkr

Namestring
Impulse Dynamics
Legal namestring
Impulse Dynamics N.V.
Company typeenum
Private
Founded yearint
1998
Descriptiontext

Impulse Dynamics is a privately held medical device company founded in 1997 by Professor Shlomo Ben-Haim (who holds 550+ patents) and headquartered in Marlton, NJ, with international commercial operations based in Frankfurt, Germany. The company develops and commercializes Cardiac Contractility Modulation (CCM) therapy, delivered via its Optimizer Smart Mini — a minimally invasive implantable pulse generator roughly the size of a pacemaker that delivers non-excitatory electrical signals during the heart's absolute refractory period to strengthen cardiac contractility without affecting rhythm. The device targets NYHA Class III heart failure patients with left ventricular ejection fraction of 25-45% who remain symptomatic despite guideline-directed medical therapy and are not candidates for cardiac resynchronization therapy (CRT) — a population representing roughly 70% of NYHA Class III patients who previously had no FDA-approved device-based treatment option.

The business model is direct sale of the Optimizer Smart Mini hardware system (and accessories such as Vesta and Guardio chargers) to hospitals and electrophysiologists, supported by an enterprise field sales motion, physician training programs, and a dedicated reimbursement support function that navigates Medicare and commercial payor coverage. The company has built a broad clinical evidence base across 80+ peer-reviewed publications and randomized trials (FIX-HF-5, FIX-HF-5C, FIX-HF-5C2), with over 12,000 patients implanted across 40+ countries. Key regulatory milestones include FDA PMA approval of the Optimizer Smart (March 2019), Optimizer Smart Mini approval (July 2021), CE Mark (October 2016), and most significantly a CMS National Coverage Determination issued October 2025 covering all FDA-indicated patients over age 18.

Impulse Dynamics has raised over $500M cumulatively across multiple private rounds from institutional medtech-focused investors including Perceptive Advisors, Redmile Group, Braidwell, Sands Capital, Alger, and Hobart Healthcare. The most recent $158M round closed in December 2025 to fund commercialization, clinical trials (INTEGRA-D and AIM HIGHer), and pipeline development of the investigational CCM-D (CCM-Defibrillator) combined system. The executive team was substantially rebuilt in 2024-2026 with senior operators from Medtronic, Boston Scientific, Biosense Webster, St. Jude Medical, and Inspire Medical Systems, suggesting a positioning toward a future IPO or strategic transaction.

Short descriptiontext

Impulse Dynamics is a privately held medical device company that develops the Optimizer Smart Mini, an implantable device delivering Cardiac Contractility Modulation (CCM) therapy to NYHA Class III heart failure patients not eligible for cardiac resynchronization therapy. It sells direct to hospitals and electrophysiologists across 40+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersMarlton, United States
HQ citystring
Marlton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiac contractility modulation, implantable medical devices, heart failure therapy, cardiac rhythm management, CCM therapy devices
Industry3 codes
PRIMARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAC
Cardiac Rhythm Management (Pacemakers, ICDs, CRT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAKABAD
Heart Failure & Transplant Cardiology
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Implantable Cardiac Devices / Cardiac Rhythm Management
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Sales
TypeHardware Sales
Description

Impulse Dynamics generates revenue through the sale of its implantable medical devices - the Optimizer Smart and Optimizer Smart Mini systems. These devices are sold to hospitals and physicians who implant them in heart failure patients. The company also sells accessories including chargers (Vesta and Guardio chargers) and programmers.

impulse-dynamics.com
2Provider Support Services
TypeProfessional Services
Description

The company provides reimbursement support services for trained physicians and facilities, including coding guidance, payment analysis, and patient access program enrollment assistance. While primarily a support function, this enables the core device revenue stream.

impulse-dynamics.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain, Infrastructure
Pricing details1 tier
1Medical device with complex reimbursement pathways - pricing not publicly available
ModelOtherBilling cadenceMulti-year contract
Notes

Device pricing is not publicly disclosed. CMS provides coverage with evidence development for CCM therapy. Medicare beneficiaries over age 18 with FDA-indicated use are covered. Additional reimbursement pathways include New Technology Add-on Payment (NTAP) and Transitional Pass-Through Payments.

impulse-dynamics.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Impulse Dynamics develops, manufactures, and commercializes the Optimizer Smart Mini implantable pulse generator, which delivers proprietary Cardiac Contractility Modulation (CCM) therapy to improve symptoms and quality of life in NYHA Class III heart failure patients who are not candidates for cardiac resynchronization therapy. The system is sold to hospitals and trained cardiac electrophysiologists and is supported by external chargers (Vesta, Guardio) and programmers, plus physician training and reimbursement support services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Patients walk on average 33.7 meters further than control group during 6-minute hall walk test
+6 more records
Product and service5 records
1Optimizer Smart Mini System
CategoryImplantable Cardiac Devices / Cardiac Rhythm Management
Description

Minimally invasive implantable pulse generator that delivers Cardiac Contractility Modulation (CCM) therapy to NYHA Class III heart failure patients with LVEF 25-45% who remain symptomatic despite guideline-directed medical therapy and are not candidates for cardiac resynchronization therapy (CRT). Delivers precisely timed non-excitatory electrical pulses during 5-7 hours of daily therapy, with one hour of weekly charging and an expected 20-year battery life. Sold to hospitals and trained cardiac electrophysiologists and heart failure specialists.

2Optimizer Smart System
CategoryImplantable Cardiac Devices / Cardiac Rhythm Management
Description

Original-generation implantable pulse generator delivering CCM therapy for NYHA Class III heart failure patients with LVEF 25-45% who are not indicated for CRT. First FDA-approved device for delivery of CCM therapy in the United States and the first to attain FDA Breakthrough Device status. Sold to hospitals and trained cardiac electrophysiologists.

3Optimizer INTEGRA CCM-D HF System
CategoryImplantable Cardiac Devices / Cardiac Rhythm Management
Description

Investigational combined CCM and defibrillation (CCM-D) implantable system designed to deliver both Cardiac Contractility Modulation therapy and ICD therapy for heart failure patients who require both modalities. Targeted at patients indicated for both CCM therapy and an implantable cardioverter defibrillator.

4Vesta and Guardio Chargers
CategoryImplantable Cardiac Device Accessories
Description

External transcutaneous charging systems (Vesta and Guardio) used to recharge the Optimizer Smart Mini implanted pulse generator on a weekly basis. Sold to hospitals and patients as accessories to the Optimizer Smart Mini system.

5Optimizer Programmer
CategoryImplantable Cardiac Device Accessories
Description

Proprietary programmer device used by clinicians to interrogate, configure, and program the implanted Optimizer Smart and Optimizer Smart Mini devices during and after implantation. Sold to hospitals and implanting physicians.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global leader in cardiac rhythm management with CRT-D, ICD, and heart failure device franchises. Competes with Impulse Dynamics for implant slots and electrophysiology mind-share, and several Impulse Dynamics executives (e.g., COO Noel Colón) are former Medtronic CRM leaders.

2Abbott
TypeBroad incumbent
Description

Through its St. Jude Medical acquisition, Abbott is a leading CRM and HF device player offering CRT, ICDs, and the CardioMEMS HF System. It competes with Impulse Dynamics in the broader HF device category and for hospital contracting leverage.

TypeBroad incumbent
Description

Major CRM and heart failure device competitor with CRT-D, ICDs, and the WATCHMAN franchise. Impulse Dynamics CEO Jason Spees is a former Boston Scientific VP of Sales, and the company is a significant account-level competitor for HF device implant share.

TypeDirect peer
Description

Privately held German CRM and electrophysiology device company offering pacemakers, ICDs, and CRT devices. Closely comparable to Impulse Dynamics in size, German commercial footprint (Impulse Dynamics Germany GmbH), and focus on CRM device innovation; CEO Spees is a former Biotronik SVP.

TypeDirect peer
Description

US-listed developer of neuromodulation devices (BAROSTIM) for heart failure — a directly comparable, novel-mechanism HF device therapy targeting an overlapping symptomatic HF patient population. Closest public-market analog in mechanism novelty and commercial stage.

TypeBroad incumbent
Description

Global structural heart and heart failure therapy leader, including transcatheter heart valves and critical care monitoring. Comparable as a scaled, profitable heart failure franchise and as a strategic acquirer of novel HF device technologies.

TypeDirect peer
Description

Public implantable medical device company (NYSE: INSP) commercializing neurostimulation therapy for obstructive sleep apnea. Highly comparable in business model — single-platform implantable therapeutic device, direct-to-physician sales, payer-driven reimbursement — and shares Impulse Dynamics' incoming CFO.

TypeEmerging player
Description

Developer of the WiSE cardiac stimulation system for wireless CRT. Emerging peer in novel-mechanism heart failure device therapy targeting a similar refractory HF patient population.

TypeEmerging player
Description

Developer of the Carillon mitral contour system for functional mitral regurgitation in heart failure. Comparable as a private, venture-backed structural heart / HF device company at a similar commercial stage.

TypeBroad incumbent
Description

Cardiac and resuscitation device company (now part of Asahi Kasei), with defibrillation, wearable cardioverter defibrillators, and HF-adjacent products. A historical Impulse Dynamics investor (2019 round) and a peer in the broader cardiac device ecosystem.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Impulse Dynamics

Implantable Cardiac Devices / Cardiac Rhythm Managementimpulse-dynamics.com

Impulse Dynamics is a privately held medical device company that develops the Optimizer Smart Mini, an implantable device delivering Cardiac Contractility Modulation (CCM) therapy to NYHA Class III heart failure patients not eligible for cardiac resynchronization therapy. It sells direct to hospitals and electrophysiologists across 40+ countries.

What Impulse Dynamics does

Impulse Dynamics is a privately held medical device company founded in 1997 by Professor Shlomo Ben-Haim (who holds 550+ patents) and headquartered in Marlton, NJ, with international commercial operations based in Frankfurt, Germany. The company develops and commercializes Cardiac Contractility Modulation (CCM) therapy, delivered via its Optimizer Smart Mini — a minimally invasive implantable pulse generator roughly the size of a pacemaker that delivers non-excitatory electrical signals during the heart's absolute refractory period to strengthen cardiac contractility without affecting rhythm. The device targets NYHA Class III heart failure patients with left ventricular ejection fraction of 25-45% who remain symptomatic despite guideline-directed medical therapy and are not candidates for cardiac resynchronization therapy (CRT) — a population representing roughly 70% of NYHA Class III patients who previously had no FDA-approved device-based treatment option.

The business model is direct sale of the Optimizer Smart Mini hardware system (and accessories such as Vesta and Guardio chargers) to hospitals and electrophysiologists, supported by an enterprise field sales motion, physician training programs, and a dedicated reimbursement support function that navigates Medicare and commercial payor coverage. The company has built a broad clinical evidence base across 80+ peer-reviewed publications and randomized trials (FIX-HF-5, FIX-HF-5C, FIX-HF-5C2), with over 12,000 patients implanted across 40+ countries. Key regulatory milestones include FDA PMA approval of the Optimizer Smart (March 2019), Optimizer Smart Mini approval (July 2021), CE Mark (October 2016), and most significantly a CMS National Coverage Determination issued October 2025 covering all FDA-indicated patients over age 18.

Impulse Dynamics has raised over $500M cumulatively across multiple private rounds from institutional medtech-focused investors including Perceptive Advisors, Redmile Group, Braidwell, Sands Capital, Alger, and Hobart Healthcare. The most recent $158M round closed in December 2025 to fund commercialization, clinical trials (INTEGRA-D and AIM HIGHer), and pipeline development of the investigational CCM-D (CCM-Defibrillator) combined system. The executive team was substantially rebuilt in 2024-2026 with senior operators from Medtronic, Boston Scientific, Biosense Webster, St. Jude Medical, and Inspire Medical Systems, suggesting a positioning toward a future IPO or strategic transaction.

Impulse Dynamics firmographics

Firmographics
Name
Impulse Dynamics
Legal name
Impulse Dynamics N.V.
Website
https://impulse-dynamics.com
Company type
Private
Founded year
1998
Operating status
Operating
Headcount range
251–500 employees
Short description
Impulse Dynamics is a privately held medical device company that develops the Optimizer Smart Mini, an implantable device delivering Cardiac Contractility Modulation (CCM) therapy to NYHA Class III heart failure patients not eligible for cardiac resynchronization therapy. It sells direct to hospitals and electrophysiologists across 40+ countries.
Ownership category
akta.pro rank

Impulse Dynamics industry classification

Industry
Product category
Implantable Cardiac Devices / Cardiac Rhythm Management
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAC
Cardiac Rhythm Management (Pacemakers, ICDs, CRT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAKABAD
Heart Failure & Transplant Cardiology

Keywords

  • Cardiac contractility modulation
  • Implantable medical devices
  • Heart failure therapy
  • Cardiac rhythm management
  • CCM therapy devices

Where Impulse Dynamics is headquartered

Location

Headquarters

HQ city
Marlton
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Impulse Dynamics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Medical Device Sales: Impulse Dynamics generates revenue through the sale of its implantable medical devices - the Optimizer Smart and Optimizer Smart Mini systems. These devices are sold to hospitals and physicians who implant them in heart failure patients. The company also sells accessories including chargers (Vesta and Guardio chargers) and programmers.
  2. Provider Support Services: The company provides reimbursement support services for trained physicians and facilities, including coding guidance, payment analysis, and patient access program enrollment assistance. While primarily a support function, this enables the core device revenue stream.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractMedical device with complex reimbursement pathways - pricing not publicly available

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

Impulse Dynamics product offering

Product offering

Core offering

Impulse Dynamics develops, manufactures, and commercializes the Optimizer Smart Mini implantable pulse generator, which delivers proprietary Cardiac Contractility Modulation (CCM) therapy to improve symptoms and quality of life in NYHA Class III heart failure patients who are not candidates for cardiac resynchronization therapy. The system is sold to hospitals and trained cardiac electrophysiologists and is supported by external chargers (Vesta, Guardio) and programmers, plus physician training and reimbursement support services.

Differentiator

Problem solved

Functional benefit

Products and services

  • Optimizer Smart Mini System Minimally invasive implantable pulse generator that delivers Cardiac Contractility Modulation (CCM) therapy to NYHA Class III heart failure patients with LVEF 25-45% who remain symptomatic despite guideline-directed medical therapy and are not candidates for cardiac resynchronization therapy (CRT). Delivers precisely timed non-excitatory electrical pulses during 5-7 hours of daily therapy, with one hour of weekly charging and an expected 20-year battery life. Sold to hospitals and trained cardiac electrophysiologists and heart failure specialists.
  • Optimizer Smart System Original-generation implantable pulse generator delivering CCM therapy for NYHA Class III heart failure patients with LVEF 25-45% who are not indicated for CRT. First FDA-approved device for delivery of CCM therapy in the United States and the first to attain FDA Breakthrough Device status. Sold to hospitals and trained cardiac electrophysiologists.
  • Optimizer INTEGRA CCM-D HF System Investigational combined CCM and defibrillation (CCM-D) implantable system designed to deliver both Cardiac Contractility Modulation therapy and ICD therapy for heart failure patients who require both modalities. Targeted at patients indicated for both CCM therapy and an implantable cardioverter defibrillator.
  • Vesta and Guardio Chargers External transcutaneous charging systems (Vesta and Guardio) used to recharge the Optimizer Smart Mini implanted pulse generator on a weekly basis. Sold to hospitals and patients as accessories to the Optimizer Smart Mini system.
  • Optimizer Programmer Proprietary programmer device used by clinicians to interrogate, configure, and program the implanted Optimizer Smart and Optimizer Smart Mini devices during and after implantation. Sold to hospitals and implanting physicians.

Quantifiable outcome

  • Patients walk on average 33.7 meters further than control group during 6-minute hall walk test
  • +6 more outcomes

Companies that use Impulse Dynamics

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Impulse Dynamics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Impulse Dynamics partnerships and signals

Strategic signal

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Impulse Dynamics competitors and assessment

Company assessment

Broad incumbents

  • Medtronic: Global leader in cardiac rhythm management with CRT-D, ICD, and heart failure device franchises. Competes with Impulse Dynamics for implant slots and electrophysiology mind-share, and several Impulse Dynamics executives (e.g., COO Noel Colón) are former Medtronic CRM leaders.
  • Abbott: Through its St. Jude Medical acquisition, Abbott is a leading CRM and HF device player offering CRT, ICDs, and the CardioMEMS HF System. It competes with Impulse Dynamics in the broader HF device category and for hospital contracting leverage.
  • Boston Scientific: Major CRM and heart failure device competitor with CRT-D, ICDs, and the WATCHMAN franchise. Impulse Dynamics CEO Jason Spees is a former Boston Scientific VP of Sales, and the company is a significant account-level competitor for HF device implant share.
  • Edwards Lifesciences: Global structural heart and heart failure therapy leader, including transcatheter heart valves and critical care monitoring. Comparable as a scaled, profitable heart failure franchise and as a strategic acquirer of novel HF device technologies.
  • ZOLL Medical: Cardiac and resuscitation device company (now part of Asahi Kasei), with defibrillation, wearable cardioverter defibrillators, and HF-adjacent products. A historical Impulse Dynamics investor (2019 round) and a peer in the broader cardiac device ecosystem.

Direct peers

  • Biotronik: Privately held German CRM and electrophysiology device company offering pacemakers, ICDs, and CRT devices. Closely comparable to Impulse Dynamics in size, German commercial footprint (Impulse Dynamics Germany GmbH), and focus on CRM device innovation; CEO Spees is a former Biotronik SVP.
  • CVRx: US-listed developer of neuromodulation devices (BAROSTIM) for heart failure — a directly comparable, novel-mechanism HF device therapy targeting an overlapping symptomatic HF patient population. Closest public-market analog in mechanism novelty and commercial stage.
  • Inspire Medical Systems: Public implantable medical device company (NYSE: INSP) commercializing neurostimulation therapy for obstructive sleep apnea. Highly comparable in business model — single-platform implantable therapeutic device, direct-to-physician sales, payer-driven reimbursement — and shares Impulse Dynamics' incoming CFO.

Emerging players

  • EBR Systems: Developer of the WiSE cardiac stimulation system for wireless CRT. Emerging peer in novel-mechanism heart failure device therapy targeting a similar refractory HF patient population.
  • Cardiac Dimensions: Developer of the Carillon mitral contour system for functional mitral regurgitation in heart failure. Comparable as a private, venture-backed structural heart / HF device company at a similar commercial stage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Impulse Dynamics social profiles

Digital presence

Impulse Dynamics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Impulse Dynamics leadership team

Management profile

Number of profiles

Profiles10 records

Impulse Dynamics funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Impulse Dynamics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Impulse Dynamics

What does Impulse Dynamics do?

Impulse Dynamics develops, manufactures, and commercializes the Optimizer Smart Mini implantable pulse generator, which delivers proprietary Cardiac Contractility Modulation (CCM) therapy to improve symptoms and quality of life in NYHA Class III heart failure patients who are not candidates for cardiac resynchronization therapy. The system is sold to hospitals and trained cardiac electrophysiologists and is supported by external chargers (Vesta, Guardio) and programmers, plus physician training and reimbursement support services.

Is Impulse Dynamics a public or private company?

Impulse Dynamics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Impulse Dynamics founded?

Impulse Dynamics was founded in 1998. It employs 251 to 500 people.

Where is Impulse Dynamics based?

Impulse Dynamics is headquartered in Marlton, United States, in the North America region.

How does Impulse Dynamics make money?

Two revenue lines are on record. Medical Device Sales are the primary driver. The others are provider Support Services.

Who are Impulse Dynamics's main competitors?

Broad incumbents on record are Medtronic, Abbott, Boston Scientific, Edwards Lifesciences and ZOLL Medical. Direct peers are Biotronik, CVRx and Inspire Medical Systems. Emerging players are EBR Systems and Cardiac Dimensions.

Does Impulse Dynamics have an API?

No public API is recorded for Impulse Dynamics.

What industry is Impulse Dynamics in?

Impulse Dynamics's product category is Implantable Cardiac Devices / Cardiac Rhythm Management. Its primary akta.pro industry code is HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation), with a secondary code of HLAHAFAC, Cardiac Rhythm Management (Pacemakers, ICDs, CRT). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireImpulse Dynamics® Presented Real-World, Late-Breaking Data Revealing Heart Failure Hospitalization Reduction and Sustained Clinical Benefits of CCM® Therapy at One YearImpulse Dynamics presented late-breaking one-year data from its U.S. Post-Approval Study of CCM Therapy at the HFSA 2026 meeting. The study of 530 patients across 71 sites showed a 34% reduction in heart failure hospitalization and 97% of patients improved or stabilized in NYHA class. The company is advancing its platform with the INTEGRA-D and AIM HIGHer trials.FinancialContent Business PageImpulse Dynamics® Presented Real-World, Late-Breaking Data Revealing Heart Failure Hospitalization Reduction and Sustained Clinical Benefits of CCM® Therapy at One YearImpulse Dynamics presented late-breaking one-year data from its U.S. Post-Approval Study of CCM therapy at the HFSA 2026 meeting, showing a 34% reduction in heart failure hospitalization and 97% of patients improved or stabilized in NYHA class. The study included 530 participants across 71 sites, with additional benefits in biomarkers and quality of life.Financial PostImpulse Dynamics® Presented Real-World, Late-Breaking Data Revealing Heart Failure Hospitalization Reduction and Sustained Clinical Benefits of CCM® Therapy at One YearImpulse Dynamics presented one-year data from its U.S. post-approval study of CCM therapy at the HFSA 2026 meeting, involving 530 patients across 71 sites. The study reported a 34% reduction in heart failure hospitalization and 97% of patients improved or stabilized in NYHA functional class. The company is advancing its platform with the INTEGRA-D and AIM HIGHer trials.Mpo-magPeter Donato Joins Diality as Chief Financial OfficerDiality Inc. has appointed Peter Donato as its new chief financial officer to support the commercialization of its Moda-flx Hemodialysis System. The appointment comes as the company continues patient enrollment in the PRESCRIBE clinical trial ahead of a planned limited market release next year. Donato brings nearly 35 years of financial leadership experience, including previous roles at Impulse Dynamics and Standard Bariatrics.PitchBookQ4 2025 Medtech VC and PE TrendsPrivate market activity in medtech surged in 2025, with both VC and PE deal value reaching multiyear highs. Hologic was taken private by Blackstone and TPG in an $18.3 billion deal, and Medline completed a major healthcare public listing. VC activity was driven by large deals including a $242.1 million raise by Impulse Dynamics, and notable exits included companies going public or being acquired.Investing.comImpulse Dynamics names Richard Buchholz as new CFO effective March 2 By Investing.comImpulse Dynamics, a medical device company focused on heart failure treatments, announced the appointment of Richard J. Buchholz as its new Chief Financial Officer, effective March 2, 2026. Buchholz previously served as CFO at Inspire Medical Systems for over a decade, during which he led the company through its 2018 IPO and helped achieve full-year profitability in 2024. The appointment follows Impulse Dynamics' recent $158 million financing round intended to support commercialization, product pipeline development, and clinical trials including the INTEGRA-D and AIM HIGHer studies.GlobeNewswireImpulse Dynamics® Announces New Chief Financial OfficerImpulse Dynamics appointed Richard J. Buchholz as CFO, effective March 2, 2026. He previously led finance at Inspire Medical Systems, where revenue grew from $3.8 million in 2014 to over $910 million in 2025. The appointment follows a $158 million financing round and a CMS coverage determination for CCM therapy.Pulse 2.0Impulse Dynamics: Over $158 Million Raised To Advance Next Generation Heart Failure DevicesImpulse Dynamics, a New Jersey-based medical device company focused on heart failure therapies, has raised over $158 million in a financing round anchored by Sands Capital and Braidwell, with participation from returning investors Redmile, Perceptive, and Alger. The company plans to use the capital to expand commercialization of its cardiac contractility modulation therapy and advance development of the investigational CCM-D HF System. The funding follows a recent National Coverage Determination from the Centers for Medicare and Medicaid Services for CCM therapy, which the company says expands access to more than 66 million individuals.FierceBiotechImpulse Dynamics clinches $158M for chronic heart failure implantImpulse Dynamics has raised over $158 million to expand production and commercial efforts for its Optimizer heart failure implant following a Medicare reimbursement expansion. The funding supports the development of the CCM-D HF System, which combines cardiac contractility modulation with defibrillator therapy, while initial trial results show 100% defibrillation success. This capital injection aims to remove access barriers for the more than 66 million U.S. patients eligible under the new national coverage determination.